节点文献

免疫原性细胞死亡诱导剂在脑胶质瘤治疗中的新进展

New progress of immunogenic cell death inducers in the treatment of glioma

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 孙志强陈谦学

【Author】 SUN Zhi-qiang;CHEN Qian-xue;Department of Neurosurgery, Renmin Hospital of Wuhan University;

【通讯作者】 陈谦学;

【机构】 武汉大学人民医院神经外科

【摘要】 脑胶质瘤是中枢神经系统最常见的原发性恶性肿瘤,即使采用手术联合术后同步放化疗等综合治疗,疗效扔较差。免疫原性细胞死亡(ICD)为一种新发现的调节性细胞死亡,可以被多种化学药物、物理刺激和生物制剂诱导,引起细胞释放多类损害相关分子模式,从而募集与激活多种免疫细胞,产生针对特定抗原的适应性免疫应答。ICD也被广泛用于诱导脑胶质瘤的抗肿瘤免疫治疗。本文简要概括ICD及其相关诱导剂的最新进展。

【Abstract】 Glioma is the most common primary malignant tumor in the central nervous system. Even with comprehensive treatments such as surgery combined with postoperative concurrent chemoradiotherapy, the therapeutic efficacy is still poor.Immunogenic cell death(ICD), a newly discovered form of regulated cell death, can be induced by various chemotherapeutic drugs,physical stimuli, and biological agents, causing cells to release multiple types of damage-associated molecular patterns, thereby recruiting and activating various immune cells and generating adaptive immune responses against specific antigens. ICD has also been widely employed to induce anti-tumor immune therapy for glioma. This paper briefly summarizes the latest advancements in ICD and its related inducers.

  • 【文献出处】 中国临床神经外科杂志 ,Chinese Journal of Clinical Neurosurgery , 编辑部邮箱 ,2024年12期
  • 【分类号】R739.41
  • 【下载频次】47
节点文献中: